Middle East And Asia Injectable Drugs Market Analysis & Forecast: 2026-2033

Middle East and Asia Injectable Drugs Market Size and Share Analysis: (2026-2033)

The Middle East and Asia injectable drugs market size is anticipated to grow at a CAGR of 8.2% with USD 615.44 Bn in 2026 and is expected to reach USD 1,068.50 Bn in 2033. The growth is mainly owing to rising chronic disease burden, growing hospital-based injectable treatment, and increasing use of biologics, vaccines, insulin, and specialty injectable drugs. For instance, Asia and the Middle East have a large diabetes and cancer patient base, thus creating higher demand for injectable therapies and facilitating wider adoption of advanced drug delivery solutions.

Key Takeaways

• The pre-filled syringes segment is projected to account for the largest share of 32.40% in 2026. The segment growth is due to the rising demand for ready-to-use injectable formats which assist in reducing dosing errors and improving safety, as well as support self-administration for chronic diseases. The data from WHO states medication-related harm affects 1 in every 30 patients, thereby facilitating safer injectable formats.
• The antibiotics segment is projected to account for the largest share of 24.80% in 2026. The segment’s growth is due to the high burden of bacterial infections, hospital-acquired infections, and increasing use of injectable antibiotics in emergency and inpatient care. WHO’s 2025 update reported that one in six laboratory-confirmed bacterial infections was resistant to antibiotics.
• The Intravenous (IV) segment is projected to account for the largest share of 52.60% in 2026. The growth is owing to faster drug action, high use in hospitals, and strong demand for IV injectables in critical care, oncology, antibiotics, and fluid therapy. The WHO’s 2024 IPC report highlights continued harm from healthcare-associated infections as well as AMR.
• The hospitals segment is projected to account for the largest share of 61.30% in 2026. The growth is owing to hospitals being the main setting for injectable drug administration, especially for emergency treatment, surgeries, intensive care, cancer therapy, and severe infections. OECD/WHO reported 2.5–2.8 hospital beds per 1,000 population across Asia-Pacific income groups in 2024.

Segmental Insights

To learn more about this report, Request Free Sample

Which Product Type Segment Dominates the Market?

On the basis of product type, the pre-filled syringes segment accounts for the largest Middle East and Asia injectable drugs market share of 32.4% in 2026. The growth of the segment is mainly driven by the rising biologic drug use, diabetes treatment, RSV prevention, and home-based injectable therapy, where ready-to-use sterile syringes reduce dose-preparation errors and support safer administration.

The WHO reported that the Eastern Mediterranean Region has diabetes prevalence of 17.6% among adults aged 20–79, with almost 85 million adults living with diabetes, thus creating sustained demand for injectable therapies. The Saudi Arabia’s official 2024 health statistics reported that 18.95% of adults aged 15+ had a chronic disease, with diabetes the most common condition at 9.1%.

A recent Asia-specific development came in April 2025, when India’s CDSCO permitted nirsevimab solution for injection in pre-filled syringe 50 mg/100 mg, supporting broader pre-filled biologic adoption.

Intravenous (IV) Segment to Secure the Largest Share

To learn more about this report, Request Free Sample

On the basis of route of administration, the Intravenous (IV) segment accounts for the largest Middle East and Asia injectable drugs market share of 52.60% in 2026. The segment is growing because IV injectable drugs are widely used in hospitals for cancer treatment, severe infections, emergency care, anesthesia, pain management, and biologic infusion therapies.

Asia reported 9.82 million new cancer cases in 2022, which is increasing the need for IV chemotherapy, immunotherapy, and supportive injectable medicines. In addition, WHO reported that antimicrobial resistance is highest in the South-East Asian and Eastern Mediterranean regions, where nearly one in three reported infections showed resistance. This is increasing the use of IV antibiotics and advanced anti-infective therapies in hospital settings.

A recent development supporting the segment is the Saudi FDA’s 2025 approval of Evkeeza 150 mg/ml concentrate for solution for infusion, which strengthens access to specialized IV biologic therapies in the Middle East.

Market Drivers

Growth of Biologics and Biosimilars is Transforming the Middle East and Asia Injectable Drugs Market

The growth of biologics and biosimilars is transforming the Middle East and Asia injectable drugs market because healthcare systems are treating more chronic diseases with injectable therapies. WHO reported that nearly 246 million people aged 30 years and above have diabetes in South-East Asia. WHO Eastern Mediterranean data also shows that almost 85 million adults aged 20–79 live with diabetes in the region. This increases demand for injectable insulin, GLP-1 drugs, monoclonal antibodies, and other biologic medicines.

A recent development is Japan PMDA’s 2026 listing of Ustekinumab BS 90 mg Syringe for subcutaneous injection, which is a biosimilar used for immune-mediated diseases. These approvals support lower-cost biologic access and improve physician confidence in biosimilar use. Overall, biologics and biosimilars are helping expand injectable drug adoption across diabetes, oncology, autoimmune, and inflammatory disease treatment in the Middle East and Asia.

A Major Breakthrough in the Middle East and Asia Injectable Drugs Market: Obesity Injectables Entering Southeast Asia

Obesity injectables are becoming a major breakthrough in the Middle East and Asia injectable drugs market as GLP-1 injectable therapies are shifting from diabetes treatment to chronic weight management. The WHO reported that South-East Asia has 6.6 million children under five and one in five adults living with overweight. Saudi Arabia’s 2024 Health Determinants Statistics also reported 23.1% adult obesity, showing strong demand potential in the Middle East.

In April 2025, Novo Nordisk released Wegovy in Thailand after receiving Thai FDA approval in the year 2023. This made Thailand one of the first Southeast Asian countries to get access to Wegovy. The launch is expected to increase the use of injectable obesity drugs through endocrinology clinics, private hospitals, and specialist obesity care centers. It also supports wider acceptance of prescription-based weight management in Asia.

Current Events and Their Impact on the Middle East and Asia Injectable Drugs Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Middle East and Asia Injectable Drugs Market Trends

• Rising diabetes and obesity cases are increasing demand for insulin, GLP-1 injectables, and long-acting injectable therapies across Asia and the Middle East.
• Growing adoption of biologics, biosimilars, insulin analogues, GLP-1 drugs, monoclonal antibodies, and oncology injectables is reshaping the product demand, thereby driving the Middle East and Asia injectable drugs market growth. The WHO has added GLP-1 therapies and rapid-acting insulin analogues to its 2025 Essential Medicines List.
• The expansion of hospital infrastructure, specialty clinics, and ambulatory care centers is increasing the use of IV, SC, as well as IM injectable drugs.
• Pre-filled syringes, auto-injectors, and injectable pens are gaining preference owing to easier self-administration, accurate dosing, and better patient compliance.
• Vaccination programs continue to support injectable drug demand, with South Asia reaching its highest-ever childhood immunization coverage in 2024, as per the WHO and UNICEF.
• Regulatory approvals are speeding up the access to advanced injectables. The Singapore’s HSA approved Wegovy pre-filled injection pens in March 2023, while its February 2025 update expanded use for adolescent obesity treatment.
• The WHO reported 830 million people living with diabetes globally in 2022, with treatment gaps remaining high in low- and middle-income countries, thereby facilitating stronger injectable therapy demand in Asia and Middle East markets.

Regional Insights

Asia Dominates Owing to the Rising Cancer Treatment and Biologics Demand

Asia accounts for 43.50% of the Middle East and Asia injectable drugs market share in 2026. The region’s growth is owing to its large patient pool, expanding hospital infrastructure, and growing use of hospital-administered injectable therapies. The demand is strongly supported by rising oncology treatment needs across China, Japan, South Korea, India, and ASEAN countries, where chemotherapy, monoclonal antibodies, infusion therapies, and supportive injectable medicines are widely used in cancer care.

The WHO Western Pacific Region reported close to 6.8 million new cancer cases in 2022 and nearly 3.5 million cancer deaths each year, highlighting the heavy treatment burden that continues to support injectable drug utilization. Growth is also driven by wider adoption of biologics and biosimilars, as healthcare systems focus on improving access to advanced therapies at more affordable costs.

A relevant development occurred in Singapore, where HSA approved AMGEVITA adalimumab solution for injection in prefilled autoinjector and prefilled syringe in August 2025, strengthening biosimilar injectable availability in Asia.

Middle East Injectable Drugs Market Trends

The Middle East is expected to record fast growth in the Middle East and Asia injectable drugs market, supported by rising hospital admissions, expanding specialty care, and higher use of injectable oncology drugs, insulin, GLP-1 therapies, vaccines, and biologics. Growth is also driven by government efforts to strengthen local pharmaceutical manufacturing, improve medicine access, and reduce dependence on imported injectable products.

IARC’s GLOBOCAN 2022 estimated 781,574 new cancer cases and 485,347 cancer deaths in the WHO Eastern Mediterranean Region, supporting higher demand for injectable chemotherapy, monoclonal antibodies, and immuno-oncology drugs. Saudi Arabia’s 2024 Health Status Statistics reported that 18.95% of adults had at least one chronic disease, with diabetes at 9.1% as the most common chronic condition, strengthening insulin demand.

Saudi Arabia’s October 2024 insulin localization agreement is an important example of regional growth in injectable drugs. The agreement supports domestic production of up to seven insulin products through partnerships with NUPCO, Sudair Pharmaceutical,

Rising Use of GLP-1 Therapies is Accelerating the Injectable Drugs Demand in China

China is expected to remain a high-value country in the Middle East and Asia injectable drugs market, driven by rising use of oncology infusions, diabetes injections, GLP-1 therapies, vaccines, and hospital-administered biologics.

IARC’s GLOBOCAN 2022 China factsheet estimated that China recorded 4,824,703 new cancer cases and 2,574,176 cancer deaths, which supports sustained demand for injectable chemotherapy, monoclonal antibodies, immuno-oncology drugs, and supportive intravenous medicines.

A recent development occurred on March 2026, when Hangzhou Sciwind Biosciences Co., Ltd. announced that China’s NMPA approved Ecnoglutide injection for chronic weight management in Chinese adults living with overweight or obesity. This approval strengthens China’s injectable metabolic drug pipeline and expands competition in the GLP-1 injectable segment.

Saudi Arabia Injectable Drugs Market Trends

Saudi Arabia dominates due to strong hospital-based demand for injectable drugs, a high diabetes and chronic disease burden, increasing use of insulin, GLP-1 drugs, oncology injectables, and government support for pharmaceutical localization.

The Saudi Arabia’s 2024 Health Status Statistics reported that 18.95% of adults had at least one chronic condition, while diabetes affected 9.1% of adults, thereby supporting the demand for injectable antidiabetic drugs.

In May 2025, Saudi Arabia inaugurated MS Pharma’s biologics plant in Riyadh 3rd Industrial City. This development supports local production of biologics and advanced injectable therapies, strengthening Saudi Arabia’s position as a regional injectable drug manufacturing hub and reducing dependence on imported high-value biologics.

Who are the Major Companies in Middle East and Asia Injectable Drugs Market

Some of the major key players in Middle East and Asia injectable drugs market are Kalbe Farma, Takeda pharmaceuticals Co. Ltd., Livzon Pharmaceutical Group, Inc., Sun Pharmaceutical Industries, Ltd., Pfizer, Inc., Sanofi, Novartis, Tabuk, Novo Nordisk, GlaxoSmithKline plc, AstraZeneca, and Gerresheimer AG.

Key News

• In December 2025, Singapore’s Health Sciences Authority (HSA) approved HYRIMOZ solution for injection in both pre-filled pen and pre-filled syringe formats. The approval expanded the availability of biosimilar injectable therapies in Singapore.
• In February 2025, Jiuyuan Genetic Biopharmaceutical submitted an application in China to seek approval for its experimental biosimilar version of Novo Nordisk’s weight-loss drug Wegovy.

Market Report Scope

Analyst Opinion

• The Middle East and Asia Injectable Drugs Market is growing because chronic disease treatment is shifting toward long-term injectable therapies. WHO reported that global diabetes cases reached 830 million in 2022, and more than half of people with diabetes were not taking medication, showing a major treatment gap that supports demand for insulin, GLP-1 injectables, and hospital-based injectable care.
• Cancer care is another strong growth driver for injectable drugs. WHO South-East Asia reported 2.37 million new cancer cases and 1.53 million deaths in 2022, while WHO’s Eastern Mediterranean region records nearly 500,000 cancer deaths annually. This increases the need for injectable chemotherapy, monoclonal antibodies, immunotherapies, biosimilars, and supportive care injectables in hospitals as well as specialty clinics.
• The market is also growing due to new injectable drug approvals. Singapore’s HSA approved Mounjaro injection for type 2 diabetes on March 1, 2023, and approved a new Wegovy indication in August 2025, supporting broader adoption of injectable metabolic therapies in Asia.

Market Segmentation

• By Product Type (Revenue, USD Bn, 2021-2033)
  • Pre-filled Syringes
    • Vaccines
    • Blood Stimulants
    • Biologics
    • Others
  • Auto-injectors
  • Pre-filled Pens
  • Pre-mixed IV Bags
    • Sedative Products (Sedation)
    • Anesthesia Products (Anesthesia)
    • Pain Management Products (Post-operative analgesic pain management)
    • Chemotherapy Products (Chemotherapy)
    • Antibacterial Products (Infectious diseases)
    • Electrolyte and Nutrition Products (Electrolyte and Nutrition)
  • Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
  • Intramuscular (IM)
  • Intravenous (IV)
  • Subcutaneous (SC)
  • Others (Epidural and Intrathecal)
• By Drug Class (Revenue, USD Bn, 2021-2033)
  • Anesthesia
  • Antibiotics
  • Antidotes
  • Antiemetic
  • Anti-infective
  • Anti-thrombolytic
  • Muscle Relaxant
  • Non Opioids
  • Opioids
  • Sedatives
  • Others
• By End User (Revenue, USD Bn, 2021-2033)
  • Hospitals
  • Clinics
  • Ambulatory Surgery Centers
• By Region (Revenue, USD Bn, 2021-2033)
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
• Key Players
  • Kalbe Farma
  • Takeda pharmaceuticals Co. Ltd.
  • Livzon Pharmaceutical Group, Inc.
  • Sun Pharmaceutical Industries, Ltd.
  • Pfizer, Inc.
  • Sanofi
  • Novartis
  • Tabuk
  • Novo Nordisk
  • GlaxoSmithKline plc
  • AstraZeneca
  • Gerresheimer AG

Sources

Primary Research Interviews:

• Injectable Drug Manufacturers
• Pharmaceutical Formulation Companies
• Contract Development and Manufacturing Organizations (CDMOs)
• Hospital Pharmacists
• Healthcare Procurement Managers
• Drug Distributors and Wholesalers
• Regulatory Affairs Experts
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• IQVIA
• Evaluate Pharma
• GlobalData Healthcare
• Others

Magazines

• Pharmaceutical Technology
• Pharma Manufacturing
• Contract Pharma
• BioPharma Dive
• European Pharmaceutical Review
• Healthcare Asia Magazine
• Others

Journals

• International Journal of Pharmaceutics
• Journal of Controlled Release
• Drug Delivery and Translational Research
• AAPS PharmSciTech
• Journal of Pharmaceutical Sciences
• Asian Journal of Pharmaceutical Sciences
• Others

Newspapers

• Financial Times
• Reuters
• Bloomberg News
• The Wall Street Journal
• The Economic Times
• Gulf News
• Nikkei Asia
• Others

Associations

• International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
• Parenteral Drug Association (PDA)
• International Generic and Biosimilar Medicines Association (IGBA)
• Asia Pacific Pharmaceutical Manufacturing Association (APPMA)
• Gulf Health Council
• Pharmaceutical Research and Manufacturers of America (PhRMA)
• Others

Public Domain Sources

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Saudi Food and Drug Authority (SFDA)
• UAE Ministry of Health and Prevention (MOHAP)
• Central Drugs Standard Control Organization (CDSCO), India
• Pharmaceuticals and Medical Devices Agency (PMDA), Japan
• National Medical Products Administration (NMPA), China
• World Bank Open Data
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years